Yefan Zhang & Zhen Huang. (2023). Ripretinib in combination with tyrosine kinase inhibitor as a late-line treatment option for refractory gastrointestinal stromal tumors: Two case reports and literature review. Frontiers Media S.A..
Chicago Style (17th ed.) CitationYefan Zhang and Zhen Huang. Ripretinib in Combination with Tyrosine Kinase Inhibitor as a Late-line Treatment Option for Refractory Gastrointestinal Stromal Tumors: Two Case Reports and Literature Review. Frontiers Media S.A., 2023.
MLA (9th ed.) CitationYefan Zhang and Zhen Huang. Ripretinib in Combination with Tyrosine Kinase Inhibitor as a Late-line Treatment Option for Refractory Gastrointestinal Stromal Tumors: Two Case Reports and Literature Review. Frontiers Media S.A., 2023.
Warning: These citations may not always be 100% accurate.